Faron Pharmaceuticals Oy (LSE:FARN) Interest Expense : £0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Faron Pharmaceuticals Oy's interest expense for the six months ended in Dec. 2023 was £ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Faron Pharmaceuticals Oy's Operating Income for the six months ended in Dec. 2023 was £ 0.00 Mil. Faron Pharmaceuticals Oy's Interest Expense for the six months ended in Dec. 2023 was £ 0.00 Mil. GuruFocus does not calculate Faron Pharmaceuticals Oy's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Faron Pharmaceuticals Oy Interest Expense Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Interest Expense Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.13

-0.14

-0.18

-1.19

-1.87

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.37	-	-	-

Faron Pharmaceuticals Oy Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Faron Pharmaceuticals Oy (LSE:FARN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Faron Pharmaceuticals Oy's Interest Expense for the six months ended in Dec. 2023 was £0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was £0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was £8.16 Mil.

Faron Pharmaceuticals Oy's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Faron Pharmaceuticals Oy's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines